Groundbreaking Test Could Spare Low Risk Breast Cancer Patients From Chemotherapy : huffingtonpost

according to huffingtonpost

Groundbreaking Test Could Spare Low Risk Breast Cancer Patients From Chemotherapy

Groundbreaking Test Could Spare Low Risk Breast Cancer Patients From Chemotherapy

A groundbreaking test which indicates whether chemotherapy will be effective could spare low risk breast cancer patients from unnecessary treatment.Until now, women with early stage breast cancer have taken the drugs as a precautionary measure following surgery or radiotherapy.But with the new test indicating the likelihood of the cancer returning, patients will be able to make a more informed decision.The Telegraph reported that around 46% of women with newly diagnosed early-stage breast cancer were deemed low risk by the test and did not need the medication.


in the same way wbhm

Study Of Breast Cancer Treatment Reveals Paradox Of Precision Medicine

Study Of Breast Cancer Treatment Reveals Paradox Of Precision Medicine

Voisin/Phanie Science SourceA major study about the best way to treat early-stage breast cancer reveals that "precision medicine" doesn't provide unambiguous answers about how to choose the best therapy."Precision doesn't mean certainty," says David Hunter, a professor of cancer prevention at Harvard's T.H.Chan School of Public Health.That point is illustrated in a large study published Wednesday in the New England Journal of Medicine, involving decisions about chemotherapy.


in the same way techtimes

Genomic Test Developed To Aid Early-Stage Breast Cancer Treatment : HEALTH : Tech Times

Genomic Test Developed To Aid Early-Stage Breast Cancer Treatment : HEALTH : Tech Times

AdvertisementResearchers have come up with a genomic test that assesses the activity in 70 genes responsible for growing and spreading cancer in the body, helping identify women with early-stage breast cancer who can skip out on chemotherapy.In a study published in The New England Journal of Medicine, researchers identified early-stage breast cancer patients who survived for five years without metastasis using a genomic test called MammaPrint.This is not the first time a genomic test has been used for a cancer-related purpose, but there is a growing recognition in how it is able to effectively identify breast cancer patients who can do away with chemo safely.However, the study is one of the most rigorous and largest, which is helpful in reassuring doctors and patients alike that the technology can be trusted.


furthermore medicalresearch

70-Gene Signature Can Help Identify Early-Stage Breast Cancer Patients Who Do Not Need Chemotherapy

70-Gene Signature Can Help Identify Early-Stage Breast Cancer Patients Who Do Not Need Chemotherapy

MedicalResearch.com Interview with:Prof. Laura van 't Veer, PhDLeader, Breast Oncology Program, and Director, Applied Genomics, UCSF Helen Diller Family Comprehensive Cancer CenterAngela and Shu Kai Chan Endowed Chair in Cancer ResearchUCSF Helen Diller Family Comprehensive Cancer CenterMedicalResearch.com: What is the background for this study?What are the main findings?Response: MINDACT was designed to involve only patients with node negative and 1 to 3 positive lymph node breast cancer.Node negative breast cancer is a cancer that has not spread to the surrounding lymph nodes and therefore has a lower risk of recurrence.